AMPAC Fine Chemicals LLC (AFC), a subsidiary of American Pacific Corporation, announced that it has entered into a manufacturing partnership with Codexis Inc., a California-based biotech company.
Under a new agreement, AFC will partner with Codexis to use Codexis' proprietary biocatalysis technology in combination with AFC's existing technologies to reduce cost, increase manufacturing efficiency and lessen environmental impact for pharmaceutical intermediates and APIs. Through this collaboration, AFC will have access to certain Codexis biocatalysts that add to the technology "toolbox" already present at AFC. AMPAC Fine Chemicals and Codexis will focus on development of new chemical processes through this collaboration that, if successful, could result in manufacturing cost reductions on a number of marketed pharmaceutical products.
"Ampac Fine Chemicals has established itself as a leader using innovative technologies such as Energetic Chemistry, Continuous Processes, commercial scale Simulated Moving Bed Chromatography and other innovative methods to bring value to our client base," stated Aslam Malik, president of AFC. "The partnership with Codexis brings the strengths of two innovative companies together to further leverage AFC's inherent skills. AFC technologies and commercial scale production capabilities have successfully enabled our customers' projects for over 50 years."
"Ampac Fine Chemicals is one of America's leading manufacturers of custom small molecule APIs," stated Joe Carleone, chief executive officer of AMPAC. "This partnership with Codexis is another example of the forward looking steps our team has made to serve our customers with the most-efficient and cost-effective manufacturing processes for their products."
